AIC
CLDX icon

Ameritas Investment Company’s Celldex Therapeutics CLDX Stock Holding History

Ameritas Investment Company’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed – – 1111
2018
Q4 		$0 Buy
+13
New +$64 ﹤0.01% 1525

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ameritas Investment Company's CLDX Position: Q1 2019 in Review

Ameritas Investment Company sold out of Celldex Therapeutics (CLDX) in Q1 2019, closing a stake of 13 shares.

Ameritas Investment Company first reported a position in CLDX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 53 funds tracked by Wall St. Rank hold CLDX as of Q1 2019.

  • Ameritas Investment Company reported no remaining Celldex Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Ameritas Investment Company sold 13 Celldex Therapeutics shares in Q1 2019.
  • Ameritas Investment Company first reported a position in Celldex Therapeutics in Q4 2018 and held it in 1 quarter.
  • Ameritas Investment Company's Celldex Therapeutics position peaked at $0 in Q4 2018.
  • 53 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2019.

Based on Ameritas Investment Company's 13F filing for Q1 2019, filed 16 May 2019.